WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 414582
Description: ONO-2921 is a Novel N-Type Ca Channel Blocker
MedKoo Cat#: 414582
Chemical Formula: C31H48N4O4S2
Exact Mass: 604.3117
Molecular Weight: 604.87
Elemental Analysis: C, 61.56; H, 8.00; N, 9.26; O, 10.58; S, 10.60
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: ONO-2921; ONO2921; ONO 2921
IUPAC/Chemical Name: 3-Thiazolidinecarboxylic acid, 4-((((1R)-1-(((cyclohexylmethyl)thio)methyl)-2-oxo-2-((1-(phenylmethyl)-4-piperidinyl)amino)ethyl)amino)carbonyl)-, 1,1-dimethylethyl ester, (4R)-
InChi Key: KCVLHOGZZRHCEW-SVBPBHIXSA-N
InChi Code: InChI=1S/C31H48N4O4S2/c1-31(2,3)39-30(38)35-22-41-21-27(35)29(37)33-26(20-40-19-24-12-8-5-9-13-24)28(36)32-25-14-16-34(17-15-25)18-23-10-6-4-7-11-23/h4,6-7,10-11,24-27H,5,8-9,12-22H2,1-3H3,(H,32,36)(H,33,37)/t26-,27-/m0/s1
SMILES Code: O=C(N1CSC[C@H]1C(N[C@@H](CSCC2CCCCC2)C(NC3CCN(CC4=CC=CC=C4)CC3)=O)=O)OC(C)(C)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 604.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Miyazaki Y, Sugihara H, Nishiura A, Kadota K, Tozuka Y, Takeuchi H. Appropriate selection of an aggregation inhibitor of fine particles used for inhalation prepared by emulsion solvent diffusion. Drug Dev Ind Pharm. 2017 Jan;43(1):30-41. doi: 10.1080/03639045.2016.1201099. Epub 2016 Jul 12. PMID: 27297256.
2: Ozeki T, Kano Y, Takahashi N, Tagami T, Okada H. Improved bioavailability of a water-insoluble drug by inhalation of drug-containing maltosyl-β-cyclodextrin microspheres using a four-fluid nozzle spray drier. AAPS PharmSciTech. 2012 Dec;13(4):1130-7. doi: 10.1208/s12249-012-9826-z. Epub 2012 Sep 1. PMID: 22945234; PMCID: PMC3513433.